Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Pharmacogenetics ; 10(1): 35-41, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10739170

ABSTRACT

Agranulocytosis is a rare, but serious adverse reaction to sulphasalazine. The polymorphic enzyme N-acetyltransferase 2 (NAT2) plays an important role in the metabolism of sulphasalazine. This study was conducted to analyse whether the risk of sulphasalazine-induced agranulocytosis is increased in slow acetylators. Patients were treated for inflammatory disease, mostly joint disease, with a mean dose of 2 g sulphasalazine daily. Thirty-nine patients reacted with agranulocytosis, while 75 patients had been treated for a minimum of 3 months without haematological side-effects. A population-based control panel of 448 individuals was used for comparison. All subjects were genotyped for NAT2 by polymerase chain reaction followed by restriction enzyme digestion. The six most common allelic variants were analysed: NAT2*4, NAT2*5A, NAT2*5B, NAT2*5C, NAT2*6 and NAT2*7. The proportion of slow acetylators was significantly higher in patients with sulphasalazine-induced agranulocytosis (69%) and population-based controls (64%) compared to patients who tolerated sulphasalazine (45%); odds ratio 2.71 [95% confidence interval (CI) 1.20; 6.15], P = 0.015, and odds ratio 2.17 (95% CI 1.32; 3.56), P = 0.002, respectively. Patients who developed agranulocytosis did not differ from population-based control subjects in the frequency of slow acetylators; odds ratio 1.25 (95% CI 0.62; 2.53), P = 0.535. The risk of agranulocytosis did not appear to be increased in slow acetylators, provided that the difference compared with sulphasalazine-treated control subjects was not due to a predominance of fast acetylators among patients with inflammatory joint disease. Instead, selection bias was suspected since more slow acetylators may have discontinued sulphasalazine therapy because of drug-intolerance.


Subject(s)
Agranulocytosis/chemically induced , Agranulocytosis/genetics , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Arylamine N-Acetyltransferase/genetics , Sulfasalazine/adverse effects , Acetylation , Adolescent , Adult , Aged , Aged, 80 and over , Agranulocytosis/blood , Agranulocytosis/enzymology , Alleles , Anti-Inflammatory Agents, Non-Steroidal/metabolism , Arthritis/drug therapy , Arylamine N-Acetyltransferase/metabolism , Case-Control Studies , Child , Female , Gene Frequency , Genetic Predisposition to Disease , Genotype , Granulocytes/drug effects , Humans , Inflammatory Bowel Diseases/drug therapy , Leukocyte Count , Male , Middle Aged , Odds Ratio , Polymerase Chain Reaction , Polymorphism, Genetic , Risk Assessment , Sulfasalazine/metabolism
2.
Acta Paediatr Scand Suppl ; 275: 102-7, 1979.
Article in English | MEDLINE | ID: mdl-291281

ABSTRACT

This paper is a provisional report from an ongoing field experiment in Uppsala, Sweden, with the aim to reduce the number of serious childhood accidents. Groups of parents have been systematically trained to function as child-environment supervisors. The experiences have been very positive so far. The child-environment supervisors have proved to possess good knowledge about how to prevent accidents. A large number of hazards have been detected and successfully eliminated. The groups are now taking an active part in the planning of new housing estates. The findings also indicate that the Child Health Organization should be able to play a more active role in the work of environmental improvement for the safety of children. A suggestion for a collective strategy for such activity has been worked out.


Subject(s)
Accident Prevention , Child Health Services/statistics & numerical data , Child , Child, Preschool , Environment Design , Humans , Methods , Parents , Safety , Sweden
SELECTION OF CITATIONS
SEARCH DETAIL
...